✦ LIBER ✦

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

✍ Scribed by M. Martin; A. Romero; M. C. U. Cheang; J. A. López García-Asenjo; J. A. García-Saenz; B. Oliva; J. M. Román; X. He; A. Casado; J. de la Torre; V. Furio; J. Puente; T. Caldés; J. A. Vidart; Sara Lopez-Tarruella; E. Diaz-Rubio; C. M. Perou

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 296 KB
Volume: 128
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1461-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase-III trial of doxorubicin and doc

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

✍ Philippe A. Cassier; Sylvie Chabaud; Véronique Trillet-Lenoir; Pierre-Yves Peaud 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 233 KB

A randomized phase-III trial of docetaxe

A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer

✍ Keun Seok Lee; Jungsil Ro; Byung-Ho Nam; Eun Sook Lee; Youngmee Kwon; Hye Soo Kw 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 285 KB

Cost–effectiveness analysis of adjuvant

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ Sang Gyu Lee; Young Geon Jee; Hyun Chul Chung; Sung-Bae Kim; Jungsil Ro; Young-H 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 231 KB

Decreased expression of BRCA2 mRNA predi

Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer

✍ Chiyomi Egawa; Yasuo Miyoshi; Yuuki Takamura; Tetsuya Taguchi; Yasuhiro Tamaki; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 99 KB 👁 2 views

Prediction of response to docetaxel by C

Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues

✍ Yasuo Miyoshi; Akiko Ando; Yuuki Takamura; Tetsuya Taguchi; Yasuhiro Tamaki; Shi 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 94 KB

## Abstract We studied the relationship between response of breast cancer to docetaxel (DOC) or cylophosphamide + epirubucin (CE) treatment and CYP3A4 mRNA expression in breast tumors. CYP3A4 inactivates DOC but not E, which is a predominant effector in CE treatment. Twenty patients with locally ad

Problems in evaluating response of prima

Problems in evaluating response of primary breast cancer to systemic therapy

✍ Giorgio Cocconi; Beatrice Di Blasio; Giampiero Alberti; Giancarlo Bisagni; Emanu 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 466 KB